Castration-resistant Prostate Cancer Clinical Trials in Toronto, Ontario
9 recruitingToronto, Ontario, Canada
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Hoffmann-La Roche100 enrolled32 locationsNCT07287150
Recruiting
Phase 3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Metastatic Castration-resistant Prostate Cancer
AstraZeneca670 enrolled90 locationsNCT07611110
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled282 locationsNCT06764485
Recruiting
Phase 1
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Advanced Metastatic Castration-resistant Prostate CancerProstate Specific Membrane Antigen (PSMA) Expression
Bayer198 enrolled35 locationsNCT06217822
Recruiting
Phase 3
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Canadian Cancer Trials Group236 enrolled14 locationsNCT06439225
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Not Applicable
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
OligoprogressiveCastration-resistant Prostate Cancer
Sunnybrook Health Sciences Centre30 enrolled1 locationNCT04838899